tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
BridgeBio Pharma: Clear Path to 2027 Profitability with Underappreciated Pipeline Upside
PremiumRatingsBridgeBio Pharma: Clear Path to 2027 Profitability with Underappreciated Pipeline Upside
9d ago
BridgeBio: Robust Attruby Launch and Late-Stage Pipeline Support Buy Rating and Path to Sustainable Cash Generation
Premium
Ratings
BridgeBio: Robust Attruby Launch and Late-Stage Pipeline Support Buy Rating and Path to Sustainable Cash Generation
10d ago
BridgeBio reports Q4 EPS ($1.00), consensus (67c)
Premium
The Fly
BridgeBio reports Q4 EPS ($1.00), consensus (67c)
10d ago
Tyra Biosciences price target raised to $53 from $37 at Wedbush
PremiumThe FlyTyra Biosciences price target raised to $53 from $37 at Wedbush
21d ago
BridgeBio price target raised to $83 from $81 at Oppenheimer
Premium
The Fly
BridgeBio price target raised to $83 from $81 at Oppenheimer
21d ago
BridgeBio (BBIO): Buy Rating Supported by Strong Phase 3 Infigratinib Data in Achondroplasia and Growing Commercial Momentum
Premium
Ratings
BridgeBio (BBIO): Buy Rating Supported by Strong Phase 3 Infigratinib Data in Achondroplasia and Growing Commercial Momentum
21d ago
BridgeBio Pharma Stock (BBIO) Blasts Up 15% on Dwarfism Pill Trial Success
PremiumMarket NewsBridgeBio Pharma Stock (BBIO) Blasts Up 15% on Dwarfism Pill Trial Success
22d ago
BridgeBio says PROPEL 3 study of oral infigratinib meets primary endpoint
Premium
The Fly
BridgeBio says PROPEL 3 study of oral infigratinib meets primary endpoint
22d ago
BridgeBio price target raised to $88 from $85 at BofA
Premium
The Fly
BridgeBio price target raised to $88 from $85 at BofA
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100